Report: Mexico s COVID-19 policies cost huge number of lives lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.
A study has found that an antibody drug produced by Regeneron Pharmaceuticals has reduced the risk of developing symptomatic Covid-19 by up t0 81%. According to the company, there were no hospitalisations of Covid-19 volunteers within the study, compared with four in the placebo group. The Wall Street Journal reports that the study has also shown the drug’s ability to reduce the risk of death or hospitalisation by about 70%. “So far, 21.3% of the U.S. population has been fully vaccinated, and 35.3% has received at least one shot”. Regeneron’s president, George D. Yancopoulos, has said the antibody cocktail may “help provide immediate protection to unvaccinated people who are exposed to the virus.”– Jarryd Neves
Regeneron said Monday it will ask the Food and Drug Administration to expand emergency use authorization for its antibody drug to be used as a preventative treatment against COVID-19.
New Phase 3 trial data finds a single shot of Regeneron s COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.
Erica Yoon for STAT
Regeneron Pharmaceuticals said Monday that a single shot of its monoclonal antibody cocktail reduced the risk that volunteers exposed to Covid-19 would develop the disease by 81%.
The study enrolled 1,500 healthy volunteers, each of whom shared a home with someone who tested positive for SARS-CoV-2, and randomized them to receive a single dose of its antibody treatment, given subcutaneously, or placebo. After 29 days, 11 patients in the treatment group developed Covid-19 compared to 59 on placebo. And for the subjects who got Covid-19 despite treatment, their symptoms resolved after one week, compared to three weeks for those on placebo. In 204 patients who had already tested positive for the SARS-CoV-2 virus at the study’s outset, the injection reduced their chances of progressing to symptomatic Covid-19 by 31%.